Eleni M. Tomazou

Eleni M. Tomazou

Auto-generated profile, based on publicly available information

Eleni M. Tomazou

St. Anna Children’s Cancer Research Institute (CCRI), Vienna, Austria

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2018 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
TGThomas G. P. Grünewald
Thomas G. P. Grünewald
FCFlorencia Cidre-Aranaz
Florencia Cidre-Aranaz
DSDidier Surdez
Didier Surdez
ETEleni M. Tomazou
Eleni M. Tomazou
ENRIQUE DE ALAVAENRIQUE DE ALAVA
ENRIQUE DE ALAVA
UDUta Dirksen
Uta Dirksen

8 July 2008 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
TDThomas A Down
Thomas A Down
VRVardhman K Rakyan
Vardhman K Rakyan
DTDaniel J Turner
Daniel J Turner
PFPaul Flicek
Paul Flicek
HLHeng Li
Heng Li
SBStephan Beck
Stephan Beck

19 September 2010 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
CBChristoph Bock
Christoph Bock
ETEleni M Tomazou
Eleni M Tomazou
ABArie B Brinkman
Arie B Brinkman
FMFabian Müller
Fabian Müller
FSFemke Simmer
Femke Simmer
AMAlexander Meissner
Alexander Meissner
Comparison of the methylation patterns of cells in different developmental or disease states can help to elucidate both normal and pathological regulatory mechanisms. Bock et al. evaluate the ability of three sequencing-based methods and one microarray-based technology to detect differentially methylated regions on a genome-wide scale. DNA methylation plays a key role in regulating eukaryotic gene expression. Although mitotically heritable and stable over time, patterns of DNA methylation frequently change in response to cell differentiation, disease and environmental influences. Several methods have been developed to map DNA methylation on a genomic scale. Here, we benchmark four of these approaches by analyzing two human embryonic stem cell lines derived from genetically unrelated embryos and a matched pair of colon tumor and adjacent normal colon tissue obtained from the same donor. Our analysis reveals that methylated DNA immunoprecipitation sequencing (MeDIP-seq), methylated DNA capture by affinity purification (MethylCap-seq), reduced representation bisulfite sequencing (RRBS) and the Infinium HumanMethylation27 assay all produce accurate DNA methylation data. However, these methods differ in their ability to detect differentially methylated regions between pairs of samples. We highlight strengths and weaknesses of the four methods and give practical recommendations for the design of epigenomic case-control studies.

24 June 2008 in Genome Research
Verified
Journal Article
Open access
PDF file
VRVardhman K. Rakyan
Vardhman K. Rakyan
TDThomas A. Down
Thomas A. Down
NTNatalie P. Thorne
Natalie P. Thorne
PFPaul Flicek
Paul Flicek
EKEugene Kulesha
Eugene Kulesha
SBStephan Beck
Stephan Beck
We report a novel resource (methylation profiles of DNA, or mPod) for human genome-wide tissue-specific DNA methylation profiles. mPod consists of three fully integrated parts, genome-wide DNA methylation reference profiles of 13 normal somatic tissues, placenta, sperm, and an immortalized cell line, a visualization tool that has been integrated with the Ensembl genome browser and a new algorithm for the analysis of immunoprecipitation-based DNA methylation profiles. We demonstrate the utility of our resource by identifying the first comprehensive genome-wide set of tissue-specific differentially methylated regions (tDMRs) that may play a role in cellular identity and the regulation of tissue-specific genome function. We also discuss the implications of our findings with respect to the regulatory potential of regions with varied CpG density, gene expression, transcription factor motifs, gene ontology, and correlation with other epigenetic marks such as histone modifications.

10 January 2010 in Nature Methods
Verified
Journal Article
Open access
PDF file
HGHongcang Gu
Hongcang Gu
CBChristoph Bock
Christoph Bock
TMTarjei S Mikkelsen
Tarjei S Mikkelsen
NJNatalie Jäger
Natalie Jäger
ZSZachary D Smith
Zachary D Smith
AMAlexander Meissner
Alexander Meissner
Reduced-representation bisulfite sequencing, optimized for DNA amounts as low as 30 nanograms and robust enough to process DNA extracted from formalin-fixed, paraffin-embedded tissue, allows genome-scale mapping of DNA methylation in many samples. Bisulfite sequencing measures absolute levels of DNA methylation at single-nucleotide resolution, providing a robust platform for molecular diagnostics. We optimized bisulfite sequencing for genome-scale analysis of clinical samples: here we outline how restriction digestion targets bisulfite sequencing to hotspots of epigenetic regulation and describe a statistical method for assessing significance of altered DNA methylation patterns. Thirty nanograms of DNA was sufficient for genome-scale analysis and our protocol worked well on formalin-fixed, paraffin-embedded samples.

30 January 2017 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
NSNathan Sheffield
Nathan Sheffield
GPGaelle Pierron
Gaelle Pierron
JKJohanna Klughammer
Johanna Klughammer
PDPaul Datlinger
Paul Datlinger
ASAndreas Schönegger
Andreas Schönegger
ETEleni M Tomazou
Eleni M Tomazou